C.D.C. Scales Back Recommendations for R.S.V. Vaccine

Fewer Americans age 60 to 74 should receive the shots, the agency concluded, citing reduced risks and a possible neurological side effect.Fewer Americans age 60 to 74 should receive the shots, the agency concluded, citing reduced risks and a possible neurological side effect.Read Moreyour-feed-science, Vaccination and Immunization, Disease Rates, Guillain-Barre Syndrome, Respiratory Syncytial Virus (RSV), Respiratory Diseases, Centers for Disease Control and Prevention, GSK PLC, Pfizer Inc, Moderna IncNYT > Health